Turbine and Mute production capacity increased to meet growing global distribution forecasts
• Production line capacity increased at ChinaMed facility to 3.9m units pa.
• Capacity increase in response to forecast demand following strong global distribution interest
August 28, 2015. Melbourne, Australia.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO) is pleased to advise it has increased its production line capacity at the ChinaMed production facility.
Rhinomed currently has two over-the-counter products on the market – the sleep/snoring aid Mute and its sports breathing technology, Turbine. The number of 3-pack units able to be produced per annum has been increased to 3.9 million units. This investment has been in response to changes in forecast demand in line with the recent distribution guidance. Further production capacity increases are being scoped in parallel to US and Asian distribution discussions.
Ongoing trade presentations and business development/partnering activities are continuing to receive a strong level of interest and the company expects to announce further details as they materialise.
Rhinomed remains committed to extending the global footprint of its Mute and Turbine brands and remains committed to its strategy of becoming a successful consumer health and medical device company.
Download a copy of the announcement HERE.